Navigation Links
Novexel to Present Four Posters at the 19th European Congress of Clinical Microbiology and Infectious Diseases in Helsinki
Date:5/17/2009

f Staphylococcus aureus in infected macrophages, (Poster P 1025). The final poster shows that NXL103 was active in vitro against both community-acquired and hospital-acquired strains of MRSA. The poster also showed that NXL103 was subject to a low spontaneous frequency of resistance (Poster P 1102).

It is Novexel's intention to seek partners for both the NXL104/ceftazidime combination and NXL103 in certain geographies.

All four posters will be available for download from Novexel's web site (http://www.novexel.com) shortly after the close of the ECCMID conference.

About Novexel

Novexel is a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the global hospital antibiotic market, which was worth an estimated US$17bn in 2008.[1]

Novexel currently has two novel antibacterials in Phase II clinical development. These are the injectable beta-lactamase inhibitor, NXL104, which is being developed in combination with the cephalosporin antibiotic ceftazidime for serious Gram negative infections, and the oral streptogramin antibiotic, NXL103, for the treatment of Gram positive infections, with a focus on treatment in the hospital setting and intravenous (IV) to oral switch. Novexel has three further programmes in preclinical development, NXL105, a novel anti-Pseudomonal antibiotic, NXL201, a novel echinocandin antifungal agent, and NXL104 in combination with ceftaroline. This latter product is being developed by Novexel's partner, Forest Laboratories (NYSE: '/>"/>

SOURCE Novexel
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Novexels NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
2. Novexels NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
3. Novexel to Present Five Posters at the Joint Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and the Infectious Disease Society of America (ICAAC/IDSA) Meeting
4. Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia
5. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
6. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
7. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
8. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
9. TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
10. Autism Studies Presented at Mid-Atlantic Research Consortium Meeting
11. Three Clinical Presentations on Tapentadol Extended Release Tablets for Chronic Pain Featured at 2009 American Pain Society Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2009)... Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS ) today announced preliminary ... weeks for the first dose cohort, 200 mg bid, in ... pegylated interferon and ribavirin (SOC) in HCV patients. 56% ... virus (<15 IU/ml) at week 4, known as R ... to 20% of patients receiving placebo plus SOC. ...
(Date:12/17/2009)... -- Decision Resources, one of the world,s leading ... healthcare issues, finds that over 70 percent of ... need for diabetes drugs with novel mechanisms of ... a high need for additional DPP-IV inhibitors. Both ... glucose lowering ability and physicians in particular say ...
(Date:12/17/2009)... CARMIEL, Israel, Dec. 17 Protalix BioTherapeutics, ... appointment of Sandra Lauterbach to Vice President, Sales ... U.S. based position, Ms. Lauterbach will be responsible ... activities for taliglucerase alfa in accordance with the ... as well as any other products that emerge ...
Breaking Medicine Technology:ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 2ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 3ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 4ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 5ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 6ANA598 Demonstrates Positive 4-Week Results at 200 mg BID 7Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors 2Over 70 Percent of Physicians Say There Is a High Need for More Diabetes Drugs with Novel Mechanisms of Action While 15 Percent Say the Same for DPP-IV Inhibitors 3Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs 2Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs 3Protalix Names Sandra Lauterbach Vice President of Sales and Commercial Affairs 4Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281 48285 1Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281 48285 2Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281 48285 3Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281 48285 4AssureRx Adds New CEO 12542 1AssureRx Adds New CEO 12542 2RainEarth Applies for Patent for Second Generation Blood Dialysis Equipment 48282 1RainEarth Applies for Patent for Second Generation Blood Dialysis Equipment 48282 2RainEarth Applies for Patent for Second Generation Blood Dialysis Equipment 48282 3
... American Society of Breast Surgeons and American College of Radiation ... ... SUNNYVALE, Calif., June 24 Xoft, Inc. today announced,the launch and ... Brachytherapy patient registry,under oversight from three national physician societies, the American,Brachytherapy ...
... Managers, DALLAS, June 23 Employers and ... role in preventing their,workers from suffering crippling or ... at U.S. Preventive Medicine, the leader in,disease prevention., ... U.S. Preventive Medicine,says it,s not uncommon for heart ...
Other Medicine Technology:First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies 2First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies 3First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies 4U.S. Preventive Medicine: Employers Can Help Workers Avoid Heart Attacks 2U.S. Preventive Medicine: Employers Can Help Workers Avoid Heart Attacks 3
(Date:12/17/2009)... feature is by Devon Herrick, PhD, Senior Fellow at ... often assume they have little control over how much ... cannot be scheduled, doctors prescribe treatments and employers provide ... However, there are many overlooked ways to trim your ... ,, Cut your prescription costs: ...
(Date:12/17/2009)... The National Council on Disability ... JW Marriott Houston, 5150 Westheimer, Houston, TX, beginning at ... at 11:00 a.m. on Thursday, January 21, 2010. This ... believes it is vital to hear from communities around ... for people with disabilities. This meeting will provide another ...
(Date:12/17/2009)... MA Brandeis University selected Jay and Maureen Neitz, the ... use of gene therapy to treat vision disorders, as ... in Vision Sciences. , The award is funded by ... gift from Brandeis graduates Jay Pepose ,75 and Susan ... graduate research fellowships in vision science. , The Neitzes, ...
(Date:12/17/2009)... the particle might someday ease accompanying lung infections , , ... severe pneumonia when infected with the swine flu virus, ... why. , A key to the severity of the ... (TH17), which helps the immune system fight off germs ... in swine-flu patients at 10 Spanish hospitals last summer ...
(Date:12/17/2009)... Studies Important ,for the R&D Informatics Industry, , ... ... Cambridge Healthtech Institute is pleased to announce the participation of ... R&D Informatics Systems conference to be held on February 3-5, ... CA. This meeting has been integrated in the Informatics Channel ...
Breaking Medicine News(10 mins):Health News:Six Ways to Slash Your Health Costs 2Health News:Six Ways to Slash Your Health Costs 3Health News:Six Ways to Slash Your Health Costs 4Health News:National Council on Disability to Hold Houston Meeting to Hear Issues Affecting People With Disabilities 2Health News:Vision researchers Jay and Maureen Neitz to receive first Pepose Award from Brandeis 2Health News:Seven World Leading IT Companies to Sponsor and Speak at CHI's Adopting R&D Informatics Systems, part of 17th International Molecular Medicine Tri-Conference 2Health News:Seven World Leading IT Companies to Sponsor and Speak at CHI's Adopting R&D Informatics Systems, part of 17th International Molecular Medicine Tri-Conference 3
... the ... EAST RUTHERFORD, N.J., Sept. 12 The New ... with the high-tech SportsAide(R) treatment,to help protect their team ... the Sports Antimicrobial System(R) (SAS), a,powerful family of treatments ...
... Care Payments, WASHINGTON, Sept. 12 Home ... and 11 for "March on Washington,and Lobby Days" ... home health payments. Participants met with their respective,members ... meeting with,representatives from 45 states., Agency members ...
... Transplanted cells don,t boost AL amyloidosis outcomes, study finds ... a disheartening result that confounds existing research, a team ... a rare kidney disease is no better than the ... and must be interpreted with caution," said Dr. S. ...
... Separate Bills, Despite the, Cloud of a ... Sept. 12 U.S. House and Senate,leaders are meeting ... of legislation that reauthorizes the 10-year-old State,Children,s Health Insurance ... how many additional children would be covered in each ...
... 12 The National Alliance,for Hispanic Health (the ... is in your Hands (Presion alta...El control,esta en ... of hypertension (high,blood pressure), promoting prevention, and helping ... The Alliance is conducting,education and blood pressure screening ...
... PRINCETON, N.J., Sept. 12 Gary S. Carter,president and ... that he,ll retire next June. Carter has been at ... the past 14 years. During,that time he has built ... and help resolve complex health policy issues. Known ...
Other Medicine News:Health News:New Jersey Nets Shoot Down Staph with High-Tech Defense 2Health News:National Association for Home Care & Hospice (NAHC) Members Take Their Case to Capitol Hill 2Health News:Stem Cell Therapy Disappoints Against Rare Kidney Ailment 2Health News:Congress Poised to Add Millions of Uninsured Children to Successful, Bipartisan Health Plan 2Health News:Congress Poised to Add Millions of Uninsured Children to Successful, Bipartisan Health Plan 3Health News:Uncontrolled Blood Pressure Highest Among Hispanics, Prompting New Hypertension Project in San Antonio 2Health News:Uncontrolled Blood Pressure Highest Among Hispanics, Prompting New Hypertension Project in San Antonio 3Health News:Hospital Association President Gary Carter Announces Retirement 2
Rapid, visual assay for the presumptive qualitative detection of Respiratory Syncytial Virus (RSV) directly from nasopharyngeal specimens in neonatel and pediatric patients....
Rapid immunochromatographic membrane test for RSV. Accepts nasopharyngeal washes, aspirates, and swabs....
A direct enzyme immunoassay for detection of gr. A rotavirus in fecal specimens....
ELISA for Anti-Proteinase 3 PR3 (cANCA)....
Medicine Products: